Key Features: Clinically proven formula that helps support GLP-1 level, metabolism and energy
2,3 Detailed results presented from SYNCHRONIZE-MASLD, showed that the trial met both its primary endpoints, with additional results showing that, relative to baseline, liver fat normalization was reached by 6 out of 10 participants living with metabolic dysfunction-associated steatotic liver disease (MASLD) and obesity or overweight who were treated with survodutide after 48 weeks
Prescription GLP-1 medications, which are approved by the FDA, are different because they are GLP-1 receptor agonists
Ozempic is a GLP-1 receptor agonist
Through customized treatment plans, expert guidance, and free consultations, they empower patients to reclaim control of their lives and embrace a healthier, happier future